IMNN vs. PPBT, ELAB, AKTX, KPRX, MBRX, MNPR, MIRA, ABVC, RDHL, and AVTX
Should you be buying Imunon stock or one of its competitors? The main competitors of Imunon include Purple Biotech (PPBT), Elevai Labs (ELAB), Akari Therapeutics (AKTX), Kiora Pharmaceuticals (KPRX), Moleculin Biotech (MBRX), Monopar Therapeutics (MNPR), MIRA Pharmaceuticals (MIRA), ABVC BioPharma (ABVC), RedHill Biopharma (RDHL), and Avalo Therapeutics (AVTX). These companies are all part of the "pharmaceutical preparations" industry.
Purple Biotech (NASDAQ:PPBT) and Imunon (NASDAQ:IMNN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk, media sentiment, community ranking and analyst recommendations.
9.6% of Purple Biotech shares are held by institutional investors. Comparatively, 4.5% of Imunon shares are held by institutional investors. 3.0% of Purple Biotech shares are held by company insiders. Comparatively, 3.8% of Imunon shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Purple Biotech received 3 more outperform votes than Imunon when rated by MarketBeat users. However, 100.00% of users gave Imunon an outperform vote while only 92.31% of users gave Purple Biotech an outperform vote.
In the previous week, Imunon had 20 more articles in the media than Purple Biotech. MarketBeat recorded 20 mentions for Imunon and 0 mentions for Purple Biotech. Purple Biotech's average media sentiment score of 0.19 beat Imunon's score of 0.00 indicating that Imunon is being referred to more favorably in the news media.
Purple Biotech presently has a consensus price target of $9.00, indicating a potential upside of 1,524.55%. Imunon has a consensus price target of $12.00, indicating a potential upside of 757.14%. Given Imunon's higher possible upside, analysts clearly believe Purple Biotech is more favorable than Imunon.
Imunon's return on equity of -57.40% beat Purple Biotech's return on equity.
Imunon has higher revenue and earnings than Purple Biotech. Imunon is trading at a lower price-to-earnings ratio than Purple Biotech, indicating that it is currently the more affordable of the two stocks.
Purple Biotech has a beta of 1.01, suggesting that its share price is 1% more volatile than the S&P 500. Comparatively, Imunon has a beta of 2.04, suggesting that its share price is 104% more volatile than the S&P 500.
Summary
Purple Biotech beats Imunon on 8 of the 15 factors compared between the two stocks.
Get Imunon News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMNN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IMNN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
